Introduction
============

Prostate cancer is the most common non-skin malignancy in men and the second leading cause of cancer-death in the United States. It develops in a series of morphologic and genetic steps that begins with the transformation of normal tissue to hyperplastic lesions, and continues to high-grade prostatic intraepithelial neoplasia (HGPIN), invasion and metastasis.

In addition to neoplastic epithelial cells, tumors also contain a highly complex microenvironment composed of a mixture of fibroblasts, myofibroblasts, endothelial cells, inflammatory cells and extracellular matrix. As tumor progresses, carcinoma cells proliferate and invade the surrounding stroma through the basement membrane. As a response to the disruption of normal tissue homeostasis, the stroma will undergo several modifications creating new stromal microenvironment termed \'reactive\' stroma which differs from the stroma in normal tissue and can promote tumorigenesis [@B1]. These modifications include proliferation of fibroblasts [@B2], lymphocyte infiltration [@B3], extracellular matrix remodeling and increased angiogenesis [@B1].

Transformed carcinoma cells which result from accumulation of genetic mutations have been the focus of cancer research for many years and they were claimed to be the trigger of malignant phenotype. However, this epithelial cell-driven tumorigenesis viewed the surrounding stroma as a passive support structure and neglected its contribution in the malignant transformation. Historically, Paget recognized the importance of tumor microenvironment in cancer progression and proposed the "seed and soil" hypothesis in 1889 [@B4]. In this hypothesis, Paget pointed out the importance of the interaction between tumor cells and microenvironment in oncogenesis and cancer progression. Recent studies provided insight into this crosstalk and identified key role of stromal cells in many steps of tumor development and invasion [@B5],[@B6]. It is now understood that microenvironmental interactions in carcinomas are crucial in cancer progression. Carcinoma associated fibroblasts (CAFs) enhanced tumor progression and transformation of nontumorigenic, immortalized human prostatic cell line [@B2]. Another principal component of reactive stroma is tumor associated macrophages. A localized increase of leukocyte infiltration was observed in malignant prostate tissue as compared to adjacent benign areas [@B3],[@B7],[@B8]. A global expression analysis of reactive stroma in prostate cancer shows differential gene expression pattern in tumor associated stroma versus normal stroma [@B9],[@B10]. Taken together, these studies underscore the stromal-epithelial interface as a critical mediator of oncogenic potential. While stromal cells are influenced by the adjacent epithelium via paracrine mechanisms, they are not just responding to these stimuli but also actively affecting the fate of adjacent epithelium. These data demonstrate that targeting the tumor microenvironment can be a feasible therapeutic strategy.

Almost all current cancer therapies target the tumor epithelial cells from which prostate carcinomas are thought to arise. However, the genetic instability of epithelial cells caused them to acquire resistance to most therapies. Now, extensive efforts are dedicated to explore therapies that target more genetically stable stromal cells that are less likely to develop resistance. Therefore, targeting tumor microenvironment in an attempt to identify novel stromal biomarkers may provide a promising opportunity for prostate cancer prevention and treatment. Toward that end, the present study focuses on proteomic analysis of stromal cells and epithelial cells in normal, benign, cancerous and inflammatory prostate tissues. Different cell types including leukocytes, myofibroblasts, endothelial cells, basal cells and epithelial cells are isolated and profiled. The identification of some molecular markers may help to understand the molecular mechanisms that govern the initiation of invasion.

Materials and Methods
=====================

Tissue preparation
------------------

Fresh frozen prostate tumor specimens were collected from our collaborator Dr. Kenneth Iczkowski. The pathologies of the prostate tissues used are normal, benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Collectively, the tissues were minced and cell suspension was prepared as described in Allinen *et al.* [@B11]. Briefly, tissues were digested into 1-2 mm pieces, incubated in 5 x volume of DMEM that contains 2 mg/mL collagenase I and 2 mg/mL hyaluronidase at 37 ºC for 2 hours. Tubes were then centrifuged at 3000 x g for 10 minutes. The supernatants were discarded. Pellets were washed with 1 x HBSS. Tubes were then centrifuged at 3000 x g for 10 minutes. Supernatant were discarded and pellets were collected. Pellets were then incubated in 10 x volume of trypsin/EDTA at 37 ºC for 5 minutes. Ice cold medium including 10% FBS was then added to the mixture as needed to filter the pellets. The mixture was then filtered through a 100 μm than 40 μm and then a 20 μm filter mesh strainer. Flow through was then centrifuged at 3000 x g for 5 minutes. Cell mixture was then collected, washed with HBSS, centrifuged at 3000 x g for 5 minutes. Cells were collected and resuspended in 200 μL/ 1 million cells with PBE.

Cell separation
---------------

Cells were separated according to the diagram in Figure [1](#F1){ref-type="fig"} using dynal beads. The beads are attached to antibodies specific to surface marker of the cells to be separated. Following the manufacturer\'s instructions, 100 μl of the dynal beads are added to the cell suspension, incubated for 20 minutes at 4 ºC with gentle tilting and rotation and placed on the magnet for 2 minutes. The bead bound cells are washed 3 times by resuspending in PBE buffer to remove contaminating cells, and then the captured cells are frozen immediately on dry ice. Unbound cells are collected by centrifugation and reconstituted in PBE buffer. Epithelial enrich dynabeads (Cat \# 161.02, Invitrogen, Carlsbad, CA), CD31 beads (Cat \# 111.55D Invitrogen, Carlsbad, CA), and equal mixture of CD45 (Cat \# 111.53D, Invitrogen, Carlsbad, CA) and CD15 (Cat \# 111.37D, Invitrogen, Carlsbad, CA) beads were used to isolate epithelial cells, endothelial cells and leukocytes respectively. CELLection Biotin Binder dynabeads (Cat \# 115.33D, Invitrogen, Carlsbad, CA) were incubated for 2 hours at RT with CD44 (Cat \# CL89153B, Cedarlane, Burlington, NC) or CD10 biotinylated antibodies (Cat \# 13-0108-82, eBioscience, San Diego, CA) to isolate basal cells or myofibroblasts respectively.

Protein extraction and quantification
-------------------------------------

Cells were lysed by adding cell lysis buffer (30 mM Tris, 7 M Urea, 4% CHAPS, protease inhibitor), followed by vortexing for 1 hour then centrifugation for 15 min at 15000g. The supernatant was used for protein quantification. Microplate bicinchoninic acid (BCA) Protein assay kit (Pierce, Rockford, IL) was used to determine the protein concentration using bovine serum albumin as a standard according to manufacturer\'s instructions. A triplicate of each sample was utilized and the mean absorbance was used to calculate the concentration of the protein using the standard curve.

Two-dimensional gel electrophoresis
-----------------------------------

Two-dimensional gel electrophoresis was performed as described previously [@B12]. Briefly, a total of 50 µg of proteins were vacuum-dried and reconstituted in 200 µL of rehydration buffer (30 mM Tris, 7 M Urea, 4% CHAPS, 50 mM DTT). Isoelectric focusing was run as first dimension using immobilized pH gradient (IPG) strips, pH 4 to 7 (Bio-Rad). This was followed by rehydration of the strips in two equilibration buffers using 2 mL for 15 min each. The first buffer constituted of 375 mM Tris-HCL pH 8.8, 6 M urea, 2% SDS and 2% DTT. The second buffer was composed of 375 mM Tris-HCL pH 8.8, 6 M urea, 2% SDS and 2% iodoacetamide. Proteins were then separated using Polyacrylamide Gel Electrophoresis (PAGE) where the strips were placed on 10% polyacrylamide gel and allowed to electrophorese at 50 V for 30 min then at 100 V till the end of separation. The cathode buffer used consisted of 0.1 M Tricine, 0.1 M Tris-HCl pH 8.2, and 0.1% SDS; whereas the anode buffer was 0.2 M Tris-HCl pH 8.9. Gels were fixed in 40% ethanol and 10% acetic acid and stained with SYPRO Ruby (Bio-Rad) for 3 hours at room temperature. Gels were destained in 10% methanol and 7% acetic acid to decrease background staining followed by washing 3 times in ddH~2~O. Typhoon 9410 Scanning Systems (GE Healthcare) was used to scan the gels. The excitation wavelength was 457 nm and the signals were detected at 550 V.

Trypsin Digestion and Matrix-assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry (MALDI-TOF MS)
-----------------------------------------------------------------------------------------------------------------

Protein digestion was performed as described previously [@B13]. Briefly, protein spots from 2DE gels were excised under UV light, combined, and incubated with trypsin overnight (Cat \# T7575, Sigma Aldrich). Peptides generated from the trypsin digestion were then mixed with a matrix (α-cyano-hydroxycinnamic acid) [@B14],[@B15] at a 100-1000 fold molar excess over the analyte [@B16]. This mixture was then spotted onto a target plate and allowed to evaporate until crystals were formed. Spectra were collected in reflectron positive ion mode over the mass range of 500 to 3000 Da. MASCOT software was used to identify the proteins. The search was performed against the SwissProt database for the *Homo sapiens* taxonomy. The following parameters were used: one missed cleavage, mass tolerance of 1.3 Da, oxidation of methionine (variable modification), and carbamidomethylation (fixed modification).

Densitometric analysis
----------------------

The density of the spots was measured using ImageJ Java-based software developed at National Institutes of Health (NIH) and available on the internet (<http://rsb.info.nih.gov/nih-image/>). It was based on the area under the curve (AUC) from rectangular image captures. Fold change was calculated as the ratio of the area of malignant state to that of normal state. Fold regulation was then measured as the following: if fold change \>1, it remained unchanged; if fold change \<1, the negative inverse of it was calculated to show downregulation.

Results
=======

Differential protein expression in different prostate tissue pathologies
------------------------------------------------------------------------

Densitometric analysis of proteins expressed in the same cell type in normal, benign, cancerous and prostatitis tissues shows different levels of expression when compared to normal tissue expression levels (Table [1](#T1){ref-type="table"}). Some proteins are upregulated, others are downregulated. Moreover, few proteins are found to be exclusively expressed either in the normal tissue or in the malignant one (Figure [2](#F2){ref-type="fig"} and Figure [3](#F3){ref-type="fig"}). For example, four proteins are upregulated and ten are downregulated in endothelial cells of the hyperplastic tissue compared to the normal one. In prostate cancer, seven spots are overexpressed and four are downexpressed, while two spots were not detected. In prostatitis, five spots are upregulated, seven spots are downregulated, and two proteins were not detected (Figure [3](#F3){ref-type="fig"}C).

Identification of some putative protein biomarkers
--------------------------------------------------

MALDI-TOF analysis followed by Mascot search resulted in the identification of a subset of proteins in different cell types (Table [2](#T2){ref-type="table"}). In leukocytes, we were able to identify GTP-binding protein (GTPB1), junctophilin, leucine-rich repeat serine/threonine-protein kinase (LRRK2), caspase1, interleukin 18 receptor (IL18R), and Rab5 GDP/GTP exchange factor (Rabex5 or RAP1). Proto-oncogene Wnt-3, uncharacterized serine/threonine-protein kinase, tyrosine-protein phosphatase non-receptor type 1(PTPN1 or PTP1B) and Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1 were found in endothelial cells. Integrin alpha-6 and poly ADP-ribose polymerase 14 were discovered in epithelial cells and myofibroblasts. Cellular retinoic acid-binding protein 2 (CRABP2) was identified in basal cells. Actin-related protein complex was found in all cell types.

Discussion
==========

The epithelium of normal and preneoplastic prostate gland is underpinned by a basal cell layer and a basement membrane which separate it from the stroma and act as messengers mediating its communication with the surrounding microenvironment [@B3]. To become invasive, carcinoma cells must first pass through the basal cell layer and the underlying basement membrane. A common diagnostic feature of prostate cancer progression from *in situ* to invasive tumor is the gradual disappearance of fully differentiated basal cell layer [@B8]. This implies that abrogation of the basal cell layer is an absolute prerequisite for tumor invasion. Whilst most of the concepts regarding disruption of the basal cell layer and the underlying basement membrane defined a prominent role of proteolytic enzymes [@B17],[@B18], clinical trials using proteinase inhibitors have been disappointing [@B3],[@B19] and only 10-30% of PIN lesions expressing high levels of proteinases become invasive [@B20],[@B21]. This suggests an alternative pathway of prostate cancer progression and invasion. Recently, numerous studies support the hypothesis that tumor microenvironment plays important roles in cancer initiation, growth, progression, invasion, and metastasis. The stroma is no longer perceived as a reactive responder to the neoplastic process, but rather as an interactive component that actively affects the fate of the adjacent epithelium.

So far, it is unknown what mechanisms lead to focal basal cell layer disruptions and its contribution to tumor progression. To identify the intrinsic mechanism of tumor initiation and progression, Man *et al*. suggested a potential role of autoimmune reactions in malignant transformation. Focally disrupted basal cell layers were correlated with higher leukocytes influx. They exhibited lower proliferation rate, lower tumor suppressor genes expression and higher apoptosis. The tumor epithelial cells overlying disrupted basal cells also showed substantial differences from other epithelial cells in the ducts. They displayed a higher proliferation rate and a higher expression of invasion and cell cycle related genes [@B3],[@B8]. Whether this hypothesis reflects the sole trigger of tumor initiation is vague and requires further investigation.

Recently, Polyak *et al.* proposed two alternative models of *in situ* to invasive carcinoma transition in mammary gland [@B22]. The "Escape" model suggests that a genetically distinct tumor epithelial cell clone will disrupt the myoepithelial cell layer and the underlying basement membrane, escape from the duct and migrate into the stroma. In the "Release" model, myoepithelial cells will cooperate with leukocytes and myofibroblasts to break down the ducts and release tumor epithelial cells. Polyak purported that the two models may not be mutually exclusive and myoepithalial cells together with infiltrating leukocytes and myofibroblasts may affect the clonal evolution of tumor epithelial cells. Moreover, recent genomic characterization of tumor microenvironment was done by the purification of all major cell types from normal breast tissue, ductal carcinoma *in situ* (DCIS), and invasive carcinomas [@B23]. They found genetic changes in all cell types of the mammary gland suggesting that tumor progression results from reciprocal interactions between epithelial and stromal cells challenging the old paradigm of epithelial cell-driven tumorigenesis. Due to similarities between mammary and prostate glands, the potential involvement of all stromal cell types in initiation of invasion in prostate cancer needs to be addressed. To elucidate this mechanism, epithelial and stromal cells were isolated from different prostate tissue pathologies. This study aims to recognize specific protein signatures that may govern the breakdown of basal cell layer, thereby leading to the initiation of tumor invasion.

2-DE of proteins extracted from epithelial cells (Figure [2](#F2){ref-type="fig"}) and stromal cells (Figure [3](#F3){ref-type="fig"}) isolated from normal, benign, cancerous, and inflammatory prostate tissues shows differential protein signatures within the same cell type in different prostate tissue pathologies that support the differential gene expression pattern found in epithelial cells and stromal cells in normal versus cancerous prostate [@B9],[@B10]. Densitometric analysis of the spots reveals distinct expression pattern among the proteins in benign, cancerous and prostatitis tissues as compared to normal tissue. Some proteins are only expressed in normal tissues, others start to appear in BPH and increase in prostate cancer suggesting their involvement in tumor initiation and progression (Table [1](#T1){ref-type="table"}).

We were able to identify some proteins in leukocytes, endothelial cells, basal cells, epithelial cells, and myofibroblasts (Table [2](#T2){ref-type="table"}). In leukocytes, caspase-1 is found in spot \# 14 and appears to be highly expressed in prostate cancer. It is a proteolytic enzyme that cleaves some components of the inflammatory response such as interleukin-1β and interleukin-18 into active peptides [@B24]. Caspase-1, also known as IL-1β-converting enzyme, is synthesized as a zymogen which is activated by cleavage and dimerization of its 10 KDa and 20 KDa subunits. It has been shown to be involved in the formation of inflammasome and the activation of inflammatory response and apoptosis [@B25]. Caspase-1 expression level was investigated in epithelial cells of hyperplastic [@B26] and malignant prostate [@B27]. The expression of caspase-1 was dramatically diminished in the hyperplastic tissue as compared to the normal control [@B26]. Moreover, its expression was completely lost in prostate cancer specimens [@B27]. However, caspase-1 expression was not reported in stromal cells of prostate cancer tissues.

Interleukin-18 receptor 1 (IL18R1), identified in leukocytes (spot \# 4), is a receptor for the proinflammatory cytokine, IL18, that determines the development and function of T and NK cells [@B28],[@B29] and is activated by caspase-1 [@B30]. Its expression increases from normal to benign to cancerous prostate tissues. It has been reported that IL18R is expressed in spleen, thymus, leukocytes, liver, lung, heart, prostate, and placenta [@B31]. Recently, a study showed that IL18 is produced by prostate cancer cell lines and its receptor IL-18R1 was found to be expressed in the poorly differentiated prostate cancer cell lines, PC-3 and DU-145, but is absent in the well differentiated LNCaP cells suggesting a correlation with tumor progression [@B32].

Rab5 GDP/GTP exchange factor or Rabex-5, also identified in leukocytes, is involved in membrane trafficking [@B33]. It displays GDP/GTP exchange activity on Rab5, a member of Ras superfamily of G proteins, by complexing with Rabaptin-5 which is a direct effector of Rab5 [@B34]. Rabex-5-Rabaptin-5 complex helps to translocate the Rab5 GTPase to the membrane enhancing membrane docking and fusion [@B33].

The proto-oncogene Wnt-3 is identified in endothelial cells. It is a member of Wnt family of proteins which are involved in oncogenesis and various developmental processes including cell proliferation, differentiation, and cell fate [@B35]. Aberrant Wnt signaling through β-catenin is known to affect prostate cancer progression and bone metastasis [@B36]. PTPN1 (protein tyrosine phosphatase non-receptor type 1, or PTP1B) is expressed in endothelial cells of normal and benign prostate. Contradictory data suggests that PTP1B has both inhibitory and stimulatory effects on tumors based on the associated proteins and the cellular context [@B37]. As a tumor suppressor, PTP1B was found to decrease tumorigenecity of v-src-expressing cells [@B38] and neu TM-transformed cells [@B39]. On the contrary, PTP1B was reported to be an oncogene associated with breast tumorigenesis [@B40] and capable of activating *src* oncogene [@B41]. Whether PTP1B is a tumor suppressor or tumor promoter or both is still debatable and requires further investigation. In the prostate, PTP1B has been linked to neuroendocrine differentiation which is associated with androgen independent tumors suggesting an implication in prostate cancer progression [@B42]. ARAP1 contains *A*rf-GAP, *R*HO-GAP, *A*nkyrin repeat, Ras-associating and five *P*H domains. Associated with the Golgi, ARAP1 can mediate cell rounding, loss of stress fibers, changes in golgi structure and filopodia [@B43]. It regulates endocytic trafficking of the epidermal growth factor receptor (EGFR) [@B44] and DR4, a receptor protein involved in apoptosis [@B45].

Cellular retinoic acid-binding protein 2 (CRABP2), identified in normal and benign prostate tissues of basal cells, is an intracellular lipid binding protein that associates with retinoic acid and mediates its actions in cell growth, differentiation, apoptosis, and anti-tumorigenesis [@B46]. CRABP2 is found to be down regulated in prostate cancer and thus, can be a novel therapeutic marker for prostate cancer [@B47].

Integrin α-6 is a member of the integrins which are cell surface receptors for extracellular matrix proteins involved in cell migration, differentiation, cell survival, and tissue organization. The laminin binding integrin α-6 expression increases in the epithelial cells as normal tissue progresses into benign and cancerous. However, its expression remained almost the same in the myofibroblasts of hyperplastic prostate but diminished in the myofibroblasts of tumorigenic prostate. Several studies have reported higher expression of α-6 integrin in invasive and migrating human prostate cancers as opposed to other integrins [@B48]. Recently, a novel variant of α-6 integrin called α-6p generated by urokinase plasminogen activator (uPA) mediated cleavage of laminin binding domain was reported to increase cellular migration and invasion on laminin substrates [@B49],[@B50], and to enhance tumor cells tropism to the laminin rich bone microenvironment [@B51],[@B52]. Moreover, inhibition of uPA-dependent α-6 integrin cleavage delayed human prostate cancer metastasis [@B52]. PARP14 is a poly ADP-ribose polymerase which catalyzes the transfer of ADP-ribose from NAD to target proteins involved in DNA damage and repair, apoptosis, and transcription and it was reported to signal B-cell survival [@B53].

Conclusion
==========

The concept of microenvironmental effects on tumor invasion constitutes a paradigm-shift from the "protease-centered" hypothesis that focuses on basement membrane degradation and the development of protease inhibitors to prevent tumor invasion and metastasis. The role of the stroma in malignant transformation is growing steadily which focuses on reciprocal interactions between the epithelium and the surrounding microenvironment. To elucidate this role in prostate cancer, we have isolated epithelial cells, basal cells, endothelial cells, myofibroblasts, and leukocytes, from human normal, prostatitis, BPH, and prostate cancer tissues to study their protein expression. The protein profiles of the different cells show differential protein signatures for each pathology. Furthermore, we were able to identify some novel molecules that may be responsible for basal cell layer disruption and disappearance during the progression of *in situ* tumors to invasive cancers. Further validation of these proteins\' identity may lead to verification of some early invasion-promoting protein biomarkers that may be targeted to prevent invasion.
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![A schematic diagram/flow chart for the isolation of epithelial cells, basal cells, endothelial cells, leukocytes, and other types of cells from normal, benign, cancerous and chronic inflammatory human prostate tissues using magnetic beads conjugated to antibodies targeting specific membrane cell markers (Adapted from Allinen *et al.* [@B23]).](jcav01p0070g01){#F1}

![Proteins detected by two dimensional gel electrophoresis with SYPRO Ruby staining of epithelial cell fractions isolated from normal, benign (BPH), cancerous (PCa) and inflammatory (prostatitis) prostate tissues. A) Epithelial cells, B) Basal cells. The first dimension separation was performed on an 11cm linear IPG strip and the second dimension separation was accomplished on a 10% polyacrylamide gel. Annotated spots were quantified using imageJ, excised, trypsin digested, and analyzed by MALDI-TOF MS.](jcav01p0070g02){#F2}

![Proteins detected by two dimensional gel electrophoresis with SYPRO Ruby staining of stromal cell fractions isolated from normal, benign (BPH), cancerous (PCa) and inflammatory (prostatitis) prostate tissues under the same experimental conditions as described in figure [2](#F2){ref-type="fig"}. A) Myofibroblasts, B) Leukocytes, C) Endothelial cells.](jcav01p0070g03){#F3}

###### 

Densitometric analysis of spots in Epithelial, Basal cells, Myofibroblasts, Leukocytes and Endothelial cells. The fold change is shown as compared to the normal. † NA: reflects no expression of the spot in the normal tissue sample. BPH, benign prostate hyperplasia. PCa, cancer of prostate. Titis, prostatitis.

  Spot\#   Epithelial   Basal   Myofibroblast   Leukocytes   Endothelial                                                                           
  -------- ------------ ------- --------------- ------------ ------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  1        NA           NA      NA              2.2          6.85          7.1     1.92    1.79    -1.64   2.16    1.54    1.76    -1.18   1.30    1.01
  2        2.01         3.26    4.07            -1.2         2.63          1.76    1.37    1.09    -2.21   1.83    1.06    1.36    1.02    1.17    -1.04
  3        1.03         2.39    1.60            -1.24        2.04          1.79    -1.10   0       -1.40   1.44    1.47    1.94    -3.41   -1.26   1.03
  4        -5.65        1.16    0               -4.21        1.38          1.7     1.04    -1.06   1.85    1.85    2.21    0       -2.13   0       0
  5        NA           NA      NA              -1.25        1.44          1.33    1.08    0       1.29    1.28    1.75    1.73    -1.52   -1.85   -2.46
  6        1.91         1.83    1.67            -1.13        1.09          -1.12   -1.63   -2.09   -1.57   1.41    1.64    0       2.37    2.60    1.58
  7        -1.29        1.46    0               -2.26        1.07          -1.24   1.01    -1.19   -1.40   1.70    2.79    0       1.62    1.29    -1.55
  8        -2.51        1.08    0               -2           -1.3          -1.34   1.32    -1.16   1.01    0       2.35    0       -1.25   -1.50   -2.74
  9        1.62         1.65    -1.25           -1.15        1.69          2.24    1.03    -1.64   -1.31   0       NA      NA      1.62    -1.04   1.37
  10       1.50         2.27    1.26            -5.26        1.22          1.13    2.03    1.71    1.76    0       NA      NA      -1.32   -1.15   -1.38
  11       1.15         1.29    0               -1.78        1.94          1.4     1.72    1.29    1.48    1.08    2.24    1.56    -1.50   1.87    -1.27
  12       1.68         1.77    2.16            -1.52        0             2.15    -1.07   -1.35   -1.19   NA      NA      0       -1.44   1.12    -1.3
  13       1.51         1.88    1.88            -1.56        1.02          1       1.02    -2.25   -1.12   0       NA      NA      -1.13   1.12    1.05
  14       1.50         1.04    2.58            1.33         1.28          1.66    1.13    1.24    1.10    -2.65   2.05    -1.71   -1.40   0       0
  15       -1.24        1.17    -1.06           -1.16        -1.07         1.15    -1.07   1.38    -1.25   0       2.47    0                       
  16       1.18         1.63    1.68            0            0             0       1.70    1.02    1.05    0       1.15    -1.29                   
  17       1.46         1.96    2.08            -3.21        1             -1.44   -1.04   -1.01   1.04    0       -1.22   -2.17                   
  18       NA           NA      NA              -2.13        1             1.01                            0       1.15    -1.29                   
  19       NA           NA      NA              -2.64        -1.97         -1.2                            0       NA      0                       
  20       1.55         1.06    1.16            -1.43        -1.05         1.04                                                                    
  21       1.12         -1.04   -1.02                                                                                                              

###### 

Proteins identified using MALDI-TOF MS and their respective densities in benign (BPH), cancerous (PCa) and inflammatory (Titis) prostate tissues.

  Spot\#   Cell type        Protein                                                                             Score   Mw       PI     BPH     PCa     Titis
  -------- ---------------- ----------------------------------------------------------------------------------- ------- -------- ------ ------- ------- -------
  14       Leukocytes       Caspase-1                                                                           69      45814    5.63   -2.65   2.05    -1.71
  8        Leukocytes       GTP-binding protein 1 (GTPB1)                                                       62      73035    8.6    0       2.35    0
  19       Leukocytes       Junctophilin-1                                                                      76      72098    9.37   0       NA      0
  12       Leukocytes       leucine-rich repeat protein kinase (LRRK2)                                          61      289568   6.35   NA      NA      0
  4        Leukocytes       Interleukin-18 receptor 1(IL18R1)                                                   63      63119    8.06   1.85    2.21    0
  3        Leukocytes       Rab5 GDP/GTP exchange factor                                                        59      80575    6.42   1.44    1.47    1.94
  2        Endothelial      Proto-oncogene Wnt-3                                                                66      40988    7.46   1.02    1.17    -1.04
  3        Endothelial      Uncharacterized serine/threonine-protein kinase                                     61      31480    9.12   -3.41   -1.26   1.03
  14       Endothelial      Tyrosine-protein phosphatase non-receptor type 1 (PTPN1)                            59      50505    5.88   -1.04   0       0
  1        Endothelial      Arf-GAP with Rho-GAP domain, ANK repeat and PH domain-containing protein 1(ARAP1)   59      163743   5.86   -1.18   1.3     1.01
  15       Basal            Actin-related protein 2/3 complex subunit 3                                         62      20761    8.78   -1.16   -1.07   1.15
  18       Basal            Cellular retinoic acid-binding protein 2 (CRABP2)                                   59      15854    5.42   -2.13   1       1.01
  13       Epithelial       Uncharacterized protein                                                             58      108689   6.68   1.51    1.88    1.88
  3        Epithelial       Integrin alpha-6                                                                    60      127751   6.39   1.03    2.39    1.6
  2        Epithelial       Poly ADP-ribose polymerase 14 (PARP14)                                              59      195627   8.21   2.01    3.26    4.07
  13       Myofibroblasts   Uncharacterized protein                                                             58      108689   6.68   1.02    -2.25   -1.12
  3        Myofibroblasts   Integrin alpha-6                                                                    60      127751   6.39   -1.1    0       -1.4
  2        Myofibroblasts   Poly ADP-ribose polymerase 14 (PARP14)                                              59      195627   8.21   1.37    1.09    -2.21
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